Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

How Gelomics is Redefining Cancer Drug Discovery

4 September 2026 · By · Wire by Fusion42

Published

4 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Australia

◆ Source

Read at blog.google →

◆ Verified

Fusion42 · 4 September 2026 · Fusion42 review

Gelomics, in partnership with Google Australia, is leveraging cloud and AI to develop 3D human tissue models that predict cancer drug efficacy, aiming to improve clinical trial design and reduce reliance on animal testing.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now access AI-powered 3D tissue models for faster cancer drug testing that reduce costly trial errors. This opens a direct path for biotech founders to offer pharma companies smarter clinical trial design tools.

◆ Coverage

1 source · 4 Sep 2026

◆ Related on Wire

◆ Topics

Biotechcancer-drug-discoverybiotech-aiclinical-trials3d-tissue-models